ESG and Sustainability

ESG and Sustainability

A woman in a lab coat holds a test tube, focused on her scientific work in a laboratory setting.

Overview

Our mission is to support the development of innovative therapies that improve patients’ lives by offering high-quality drug development and discovery services. We strive for a balance between economic value for shareholders and positive impact on society and the environment, as well as compliance with corporate governance principles. 

In 2024, we conducted a double materiality analysis (DMA) to better manage risk, make strategic decisions and increase transparency. Selvita continues to invest in research infrastructure, process optimization and employee development, as well as increasing the transparency of its operations. 

Group Strategy for 2026+ 

One of the key objectives for 2025 is to develop a sustainable development strategy as part of the Group’s strategy for 2026+, based on: 

 

  • Calculation of the carbon footprint in three emission scopes,
  • Double materiality analysis, taking into account ESG risks.

 

Our contribution

Selvita, as an innovative research organization, plays an important role in the chain of services related to the area of drug discovery, concentrating its competences in therapeutic areas with unmet medical needs, such as oncology, neurology, infectious diseases, inflammatory diseases, fibrosis, respiratory diseases and metabolic disorders (e.g. obesity, diabetes). In line with the UN Sustainable Development Goal, Selvita strives to improve public health by providing innovative therapeutic solutions that aim to reduce the global burden of disease and improve the quality of life of patients.

Our contribution to sustainable development:

  • Advancement in innovative research on the treatment of diseases with high unmet medical needs
  • Reduction of time and cost of preclinical studies, thus accelerating patient access to modern therapies
  • Collaboration with global partners to facilitate the efficient and effective implementation of innovative medicines

Environment

In 2024, an analysis of the carbon footprint, i.e. greenhouse gas emissions in accordance with the international GHG Protocol Corporate Accounting and Reporting Standard, was carried out for the entire Group in scopes 1, 2 and 3. The year 2024 has been adopted as the base year for setting carbon footprint reduction targets in individual scopes. 

Social issues

Selvita shapes its work environment based on the values of cooperation, excellence, passion, commitment and integrity, which have been developed together with employees. These values are promoted from the first days of work through implementation programs, trainings and initiatives such as “Selvita Super Powers”.

In 2024, we hired people from 26 countries. We are proud to support everyone in the process of adapting to the new environment, taking care of comfort and integration. In addition, in 2024 we conducted over 14,600 hours of specialist training. We believe that development is the key to success – both for the individual and the entire organization. 

Cybersecurity

We make cybersecurity a priority, investing in security systems, employee training, and incident response plans to prevent attacks. In July 2024, the Group’s audit showed a score of 942 points out of 1000, which demonstrates a high level of maturity of cybersecurity practices. The Group is constantly implementing innovative solutions to raise data protection standards even more effectively.  

ESG Reports

  • Selvita Group’s Sustainability Report